Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

TY - JOUR

T1 - Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

AU - Hoejberg, Lise

AU - Bastholt, Lars

AU - Johansen, Julia S

AU - Christensen, Ib Jarle

AU - Gehl, Julie

AU - Schmidt, Henrik

PY - 2012/8

Y1 - 2012/8

N2 - Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P

AB - Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P

U2 - 10.1097/cmr.0b013e3283550aa5

DO - 10.1097/cmr.0b013e3283550aa5

M3 - Journal article

C2 - 22617301

SN - 0960-8931

VL - 22

SP - 287

EP - 293

JO - Melanoma Research

JF - Melanoma Research

IS - 4

ER -